Diffúz nagy B-sejtes limfóma (DLBCL): vizsgálatok itt: Magyarország
5 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Where
- Budapest VIII, Budapest XII, Debrecen, Nyíregyháza, Szekszárd
- Életkor
- 18 év and over
- People
- 1046 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00 - 1/2. fázisTaking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Budapest
- Életkor
- 6 hónap to 25 év
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - 2. fázisTaking peopleDALY II USA/ MB-CART2019.1 for DLBCL
- Where
- Debrecen
- Életkor
- 18 év and over
- People
- 315 worldwide
- Run by
- Miltenyi Biomedicine GmbH
See details and how to joinNCT04792489 · EU 2023-508508-39-01 - 2. fázisTaking peopleEfficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
- Where
- Budapest IX, Debrecen
- Életkor
- 18 év to 70 év
- People
- 213 worldwide
- Run by
- Miltenyi Biomedicine GmbH
See details and how to joinNCT04844866 · EU 2023-506270-13-00 - 2. fázisTaking peopleDPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Where
- Debrecen, Nyíregyháza
- Életkor
- 18 év and over
- People
- 102 worldwide
- Run by
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
See details and how to joinNCT04920617